ADAPTIVE PREDICTION OF SYMPTOMS RETURN UPON DISCONTINUATION OF OMALIZUMAB TREATMENT IN CHRONIC SPONTANEOUS URTICARIA PATIENTS

Author(s)

Saldana Miranda D¹, Ferrer M², Janssens N¹, Gimenez-Arnau A³, Balp M¹, Khalil S¹, Risson V¹
¹Novartis Pharma AG, Basel, Switzerland, ²Clínica Universitaria de Navarra, Pamplona, Spain, ³Hospital del Mar. Parc de Salut Mar, Barcelona, Spain

Presentation Documents

PRM117--strong-u-saldana-miranda-d-u-sup-1-sup-strong-ferrer-m-sup-2-sup-janssens-n-sup-1-sup-gimenez-arnau-a-sup-3-sup-balp-m-sup-1-sup-khalil-s-sup-1-sup-risson-v-sup-1-sup-br-sup-1-sup-novartis-pharma-ag-basel-switzerland-sup-2-sup-clini ...

OBJECTIVES: In patients with chronic spontaneous (CSU), who remain symptomatic despite the use of anti-histamines, omalizumab significantly improved outcomes in three Phase III randomized clinical trials. We aimed to identify characteristics that could predict the speed of symptoms recurrence after treatment discontinuation, and explore the potential relationship between the timing of response onset and the speed of symptoms recurrence in CSU patients treated with omalizumab.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PRM117

Topic

Methodological & Statistical Research

Topic Subcategory

Modeling and simulation

Disease

Sensory System Disorders

Explore Related HEOR by Topic

Methodology

Presentation